N-Glycome changes reflecting resistance to platinum-based
chemotherapy in ovarian cancer

J 2021

N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer

ZAHRADNÍKOVÁ, Martina, Ivana IHNATOVÁ, Erika LATTOVÁ, Lukáš UHRÍK, Eliška STUCHLÍKOVÁ et. al.

Základní údaje

Originální název

N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer

Autoři

ZAHRADNÍKOVÁ, Martina (203 Česká republika), Ivana IHNATOVÁ (703 Slovensko, domácí), Erika LATTOVÁ (703 Slovensko, garant, domácí), Lukáš UHRÍK (703 Slovensko), Eliška STUCHLÍKOVÁ (203 Česká republika), Rudolf NENUTIL (203 Česká republika), Dalibor VALÍK (203 Česká republika), Monika NÁLEŽINSKÁ (203 Česká republika), Josef CHOVANEC (203 Česká republika), Zbyněk ZDRÁHAL (203 Česká republika, domácí), Bořivoj VOJTĚŠEK (203 Česká republika), Lenka HERNYCHOVÁ (203 Česká republika) a Miloš NOVOTNÝ (840 Spojené státy)

Vydání

JOURNAL OF PROTEOMICS, Elsevier, 2021, 1874-3919

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

fulltext

Impakt faktor

Impact factor: 3.855

Kód RIV

RIV/00216224:14740/21:00121165

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1016/j.jprot.2020.103964

UT WoS

000597303500009

Klíčová slova anglicky

Ovarian cancer; N-Glycans; MALDI-TOF-MS

Štítky

CF PROT, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 11. 2024 20:41, Ing. Martina Blahová

Anotace

V originále

A number of studies have reported aberrant glycosylation in connection with malignancy. Our investigation further expands on this topic through the examination of N-glycans, which could be associated with the resistance of advanced stage, high-grade non-mucinous ovarian cancer to platinum/taxane based chemotherapy. We used tissue samples of 83 ovarian cancer patients, randomly divided into two independent cohorts (basic and validation). Both groups involved either cases with/without postoperative tumor residue or the cases determined either resistant or sensitive to this chemotherapy. In the validation cohort, preoperative serum samples were also available. N-glycans released from tumors and sera were permethylated and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS analysis yielded a consecutive detection of 68 (tissue) and 63 (serum) N-glycan spectral signals. Eight of these were found to be differentially abundant in tissues of both independent cohorts including the cases with a postoperative cancer residue. One of these glycans was detected as differentially abundant in sera of the validation cohort. No statistically significant differences in intensities due to the same N-glycans were found in the cases without postoperative macroscopic residues in either the basic or validation cohort. From the biochemical point of view, the statistically significant N-glycans correspond to the structures carrying bisecting (terminal) GlcNAc residue and tetra-antennary structures with sialic acid and/or fucose residues. Among them, six tissue N-glycans could be considered potential markers connected with a resistance to chemotherapy in ovarian cancer patients. The prediction of primary resistance to standard chemotherapy may identify the group of patients suitable for alternative treatment strategies. Significance: Drug resistance has become a major impediment to a successful treatment of patients with advanced ovarian cancer. The glycomic measurements related to cancer are becoming increasingly popular in identification of the key molecules as potential diagnostic and prognostic indicators. Our report deals with identification of differences in N-glycosylation of proteins in tissue and serum samples from the individuals showing sensitivity or resistance to platinum/taxane-based chemotherapy. The detection sensitivity to chemotherapy is vitally important for these patients.

Návaznosti

EF15_003/0000469, projekt VaV

Název: Cetocoen Plus

EF17_050/0008496, projekt VaV

Název: MSCAfellow@MUNI

LM2018121, projekt VaV

Název: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI

90127, velká výzkumná infrastruktura

Název: CIISB II

Citovat

ZAHRADNÍKOVÁ, Martina, Ivana IHNATOVÁ, Erika LATTOVÁ, Lukáš UHRÍK, Eliška STUCHLÍKOVÁ, Rudolf NENUTIL, Dalibor VALÍK, Monika NÁLEŽINSKÁ, Josef CHOVANEC, Zbyněk ZDRÁHAL, Bořivoj VOJTĚŠEK, Lenka HERNYCHOVÁ a Miloš NOVOTNÝ. N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer. JOURNAL OF PROTEOMICS. Elsevier, 2021, roč. 230, JAN, s. "103964", 13 s. ISSN 1874-3919. Dostupné z: https://dx.doi.org/10.1016/j.jprot.2020.103964.

@article{1745080,
   author = {Zahradníková, Martina and Ihnatová, Ivana and Lattová, Erika and Uhrík, Lukáš and Stuchlíková, Eliška and Nenutil, Rudolf and Valík, Dalibor and Náležinská, Monika and Chovanec, Josef and Zdráhal, Zbyněk and Vojtěšek, Bořivoj and Hernychová, Lenka and Novotný, Miloš},
   article_number = {JAN},
   doi = {http://dx.doi.org/10.1016/j.jprot.2020.103964},
   keywords = {Ovarian cancer; N-Glycans; MALDI-TOF-MS},
   language = {eng},
   issn = {1874-3919},
   journal = {JOURNAL OF PROTEOMICS},
   title = {N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S1874391920303328?via%3Dihub},
   volume = {230},
   year = {2021}
}

TY  - JOUR
ID  - 1745080
AU  - Zahradníková, Martina - Ihnatová, Ivana - Lattová, Erika - Uhrík, Lukáš - Stuchlíková, Eliška - Nenutil, Rudolf - Valík, Dalibor - Náležinská, Monika - Chovanec, Josef - Zdráhal, Zbyněk - Vojtěšek, Bořivoj - Hernychová, Lenka - Novotný, Miloš
PY  - 2021
TI  - N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer
JF  - JOURNAL OF PROTEOMICS
VL  - 230
IS  - JAN
SP  - "103964"
EP  - "103964"
PB  - Elsevier
SN  - 18743919
KW  - Ovarian cancer
KW  - N-Glycans
KW  - MALDI-TOF-MS
UR  - https://www.sciencedirect.com/science/article/pii/S1874391920303328?via%3Dihub
N2  - A number of studies have reported aberrant glycosylation in connection with malignancy. Our investigation further expands on this topic through the examination of N-glycans, which could be associated with the resistance of advanced stage, high-grade non-mucinous ovarian cancer to platinum/taxane based chemotherapy. We used tissue samples of 83 ovarian cancer patients, randomly divided into two independent cohorts (basic and validation). Both groups involved either cases with/without postoperative tumor residue or the cases determined either resistant or sensitive to this chemotherapy. In the validation cohort, preoperative serum samples were also available. N-glycans released from tumors and sera were permethylated and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS analysis yielded a consecutive detection of 68 (tissue) and 63 (serum) N-glycan spectral signals. Eight of these were found to be differentially abundant in tissues of both independent cohorts including the cases with a postoperative cancer residue. One of these glycans was detected as differentially abundant in sera of the validation cohort. No statistically significant differences in intensities due to the same N-glycans were found in the cases without postoperative macroscopic residues in either the basic or validation cohort. From the biochemical point of view, the statistically significant N-glycans correspond to the structures carrying bisecting (terminal) GlcNAc residue and tetra-antennary structures with sialic acid and/or fucose residues. Among them, six tissue N-glycans could be considered potential markers connected with a resistance to chemotherapy in ovarian cancer patients. The prediction of primary resistance to standard chemotherapy may identify the group of patients suitable for alternative treatment strategies. Significance: Drug resistance has become a major impediment to a successful treatment of patients with advanced ovarian cancer. The glycomic measurements related to cancer are becoming increasingly popular in identification of the key molecules as potential diagnostic and prognostic indicators. Our report deals with identification of differences in N-glycosylation of proteins in tissue and serum samples from the individuals showing sensitivity or resistance to platinum/taxane-based chemotherapy. The detection sensitivity to chemotherapy is vitally important for these patients.
ER  -

ZAHRADNÍKOVÁ, Martina, Ivana IHNATOVÁ, Erika LATTOVÁ, Lukáš UHRÍK, Eliška STUCHLÍKOVÁ, Rudolf NENUTIL, Dalibor VALÍK, Monika NÁLEŽINSKÁ, Josef CHOVANEC, Zbyněk ZDRÁHAL, Bořivoj VOJTĚŠEK, Lenka HERNYCHOVÁ a Miloš NOVOTNÝ. N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer. \textit{JOURNAL OF PROTEOMICS}. Elsevier, 2021, roč.~230, JAN, s.~''103964'', 13 s. ISSN~1874-3919. Dostupné z: https://dx.doi.org/10.1016/j.jprot.2020.103964.

Podrobný výpis o publikaci